HCW Biologics Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
HCWB$1.02-1.9%Stored close · as of Nov 6, 2026
Contents
Statements of operations
Condensed Statements of Operations
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2023 | 2024 | |
| Revenues: | ||
| Revenues | $41,883 | $1,126,712 |
| Cost of revenues | (29,350) | (511,965) |
| Net revenues | 12,533 | 614,747 |
| Operating expenses: | ||
| Research and development | 2,255,813 | 2,123,284 |
| General and administrative | 3,117,290 | 5,985,126 |
| Total operating expenses | 5,373,103 | 8,108,410 |
| Loss from operations | (5,360,570) | (7,493,663) |
| Interest expense | (93,438) | — |
| Other (expense) income, net | 383,322 | 25,602 |
| Net loss | $(5,070,686) | $(7,468,061) |
| Net loss per share, basic and diluted | $(0.14) | $(0.20) |
| Weighted average shares outstanding, basic and diluted | 35,883,779 | 37,223,588 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.